Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2] According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of 30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of 27 with concomitant obesity-related risk factors or diseases[3].The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27--29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]
Products sold by AxonPeptide are intended solely for laboratory research and analytical purposes
The benzyl alcohol is your line of defense, ensuring the solution remains sterile and safe for its intended lifespan
Every plan is tailored to the individual, creating a comprehensive, resultsdriven approach guided by one of the most experienced specialists in the field
You also acknowledge and agree that you have read the Terms of Service available on this website and agree that your rights and responsibilities are governed by the Terms of Service on this website
$44.99 $716.99Price range: $44.99 through $716.99 In stock 5-Amino-1MQ is a small-molecule NNMT inhibitor studied in metabolic and cellular energy laboratory research
